SLDB241220P15000
- 0.00
- 0.000.00%
Solid Biosciences Newsroom
Solid Biosciences Reports Increased Losses Amid R&D Focus
Solid Biosciences to Present at the Jefferies London Healthcare Conference
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $12
Solid Biosciences Price Target Lowered to $12 From $15 at JPMorgan
Solid Biosciences Price Target Maintained With a $15.00/Share by Chardan Capital
Solid Biosciences Is Maintained at Buy by Chardan Capital
Solid Biosciences Analyst Ratings
Solid Biosciences to Participates in a Conference Call Hosted by JPMorgan
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $15 to $20
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Strategic Advancements and Optimized Approaches Drive Buy Rating for Solid Biosciences
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Express News | HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Solid Biosciences GAAP EPS of -$0.79 Beats by $0.02
William Blair Initiates Solid Biosciences(SLDB.US) With Buy Rating
Express News | Solid Biosciences Inc: Has Anticipated Cash Runway Into 2026
Solid Biosciences | 10-Q: Q3 2024 Earnings Report
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates